. 2021 Feb 4;22(4):1580. doi: 10.3390/ijms22041580

Table 2.

Array-CGH results.

Patient	Sample	Follow Up	OS	CNAs
Patient	Sample	Follow Up	OS	Total	Gain	Loss
1	LM1	NED	6	110	106	4
2	LM2	NED	12	123	114	9
3	LM3	n.a.	2	268	239	29
4	STUMP1	n.a.	5	25	23	2
4	STUMP2	n.a.	5	17	17	0
5	STUMP3	DOD	2	365	342	23
5	US1	DOD	2	28	28	0
6	STUMP4	DOD	7	256	238	18
6	LMS1	DOD	7	126	121	5
7	STUMP5	DOD	1	58	58	0
7	n.a.	DOD	1
8	n.a.	ALIVE	13
8	STUMP6	ALIVE	13	116	108	8
9	n.a.	NED	8
9	STUMP7	NED	8	94	88	6
10	STUMP8	NED	14	88	80	8
11	STUMP9	ALIVE	9	82	81	1
12	STUMP10	n.a.	10	40	38	2
13	STUMP11	NED	18	97	97	0
14	STUMP12	NED	10	156	155	1
15	STUMP13	NED	16	85	81	4
16	STUMP14	NED	7	59	58	1
17	LMS2	ALIVE	8	204	194	10
18	LMS3	n.a.	n.a	199	189	10
19	LMS4	DOD	7	262	234	28
19	n.a.	DOD	7
20	n.a.	AWD
	LMS5		23	166	148	18
	n.a.

LM: leiomyoma, STUMP: smooth muscle tumors of uncertain malignant potential, LMS: leiomyosarcoma, US: undifferentiated sarcoma, NED: no evidence of disease, AWT: alive with tumor, DOD: dead of disease, OS: overall survival (years from the first tumor).